Baxdrostat (Baxfendy®), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension

“My hope is that we are entering an era where we can achieve better blood pressure control rates, given that some estimates suggest less than 30% of patients with hypertension in the United States have their blood pressure controlled. A major question that remains unanswered is how easily patients will be able to access new, nongeneric medications to treat hypertension. The field has so many generic drugs that the hoops clinicians will need to go through after prescribing baxdrostat, such as step therapy or prior authorization, remain unclear.”

“We have been waiting for an innovative medication like Baxfendy for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension. In addition, the nearly double-digit placebo-adjusted systolic blood pressure reduction achieved with Baxfendy is exciting and clinically meaningful for clinicians and patients. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events.”

“Innovation in pharmacotherapy for hypertension, including new targets like aldosterone synthase, opens doors to new frontiers in biologically-directed therapy and new hope for improved control of resistant disease.”